Expansion and differentiation of inner ear supporting cells and methods of use thereof
This disclosure relates to methods for expanding inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) and differentiating inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) to inner ear hair cells (e.g., atonal homolog 1 (Atoh1)+ inner ear hair cells) and the use of the inner hear supporting cells and hair cells, e.g., for identifying candidate therapeutic compounds for the treatment of hearing loss and balance loss. Additionally, the methods described herein can be used in the treatment of a subject having hearing loss and balance loss that would benefit from increased proliferation and differentiation of inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells).
1. A method of treating a subject having hearing loss or balance loss, the method comprising administering to the subject in need thereof a therapeutically effective amount of a protein degradation inhibitor and a therapeutically effective amount of a Notch signaling inhibitor, wherein the protein degradation inhibitor is not Epigallocatechin-3-gallate.
2. The method of claim 1 , wherein the protein degradation inhibitor and the Notch inhibitor are administered systemically or to the ear of the subject, preferably transtympanically to the middle ear of the subject.
3. The method of claim 1 , wherein the subject has hearing loss.
4. The method of claim 3 , wherein the hearing loss is sensorineural hearing loss.
5. The method of claim 3 , wherein the hearing loss is the result of a genetic or congenital defect, trauma, aging, or chemical-induced ototoxicity.
6. The method of claim 1 , wherein the subject is a human.
7. The method of claim 1 , wherein the protein degradation inhibitor is selected from the group consisting of MG132, MG262, MG115, Z-Leu-Leu-Phe-CHO, N-Acetyl-leucyl-leucyl-norleucinal, N-acetyl-leucyl-leucyl-methional, N-benzyloxycarbonyl-isoleucyl-γ-t-butyl-glutamyl-alanyl-leucinal, N-benzyloxycarbonyl-leucyl-leucyl-leucinal, N-benzyloxycarbonyl-leucyl-leucyl-tyrosyl α-keto aldehyde, N-benzyloxycarbonyl-leucyl-leucyl-phenylalanal, N-benzyloxycarbonyl-leucyl-leucyl-leucyl boronic acid, Bortezomib, Lactacystin, Disulfiram, Salinosporamide A, Carfilzomib, epoxomicin, Ixazomib, ixazomib citrate, VLX1500 (b-AP15), clasto-Lactacystin beta Lactone, Gliotoxin, AM 114 (3,5-Bis-[benzylidene-4-boronic acid]-1-methylpiperidin-4-one), PSI (N-[(Phenylmethoxy)carbonyl]-L-isoleucyl-L-α-glutamyl-tert-butyl ester-N-[(1S)-1-formyl-3-methylbutyl]-alaninamide), Oprozomib, Delanzomib, BI8622, and BI8626.
8. The method of claim 1 , wherein the Notch signaling inhibitor is selected from the group consisting of LY411575, L-685458, DBZ (Dibenzazepine), MRK560 (N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide), MRK-003, MK-0752 (3-(((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid), Compound W (3,5-Bis(4-nitrophenoxy)benzoic acid), Compound E (GSI-XXI), BMS 2289948, BMS-433796, IN973, Flurbiprofen, JLK2, JLK4, JLK6, JLK7, Begacestat, DFK167, and PF-0308414.
9. The method of claim 2 , wherein the protein degradation inhibitor and the Notch inhibitor are administered transtympanically to the middle ear of the subject.